1FISHER B,BROWN A M,DIMITROV N V,et al.Two months of doxorubicin cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrexate,and fluorouracil in positive node breast cancer patients with tamoxifen nonresponsive tumors:results from the National Surgical Adjuvant Breast and Bowel Project B215[J].J Clin Oncol,1990,8(9):1483.
2Early Breast Cancer Trialists Collbaborative Group.Polychemotherapy for early breast cancer:an overview of the randomized trials[J].Lancet,1998,352(9132):930-942.
3HENDERSON I C,BERRY D A,DEMETRI G D,et al.Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer[J].J Clin Oncol,2003,21 (6):976-983.
4HEYS S D,SARKAR T,HUTCHEON A W.Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer[J].Expert Opin Pharmacother,2004,5 (10):2147-2157.
5KUERER H M,NEWMAN L A,SMITH T L,et al.Clinical course of breast cancer patients with complete pathologic primary tumor and auxillarylymph node response to doxorubicin based neoadujvant chemotherapy[J].J Clin Oncol,1999,17(2):460-469.
6DEO S V S,BHUTANI M,SHUKLA N,et al.Randomized trial comparing neo adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer(T4bN0-2M0)[J].Oncol Surg,2003,84(1):192-197.
10INAJI H,KOMOIKE Y,MOTOMURA K,et al.Breast conserving treatment after neoadjuvant chemotherapy in large breast cancer[J].Breast Cancer,2002,9(1):20-25.
3Jones AL,Smith IE,O'Brien MER,et al. Phase Ⅱ study of continous infusion fluorourcil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol,1994,12(6) :1 259.
4O' Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda(capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years. Proc Am Soc Clin Oncol, 1998,17 : 103a.
5Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs,2000,18(4) :343.
6Talbot DC, Moiseyenko V, O'Reilly SM, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracydines. Br J Cancer, 2002,86 ( 9 ) : 1 367.
7Blum JL,Jones SE, Buzdar AU, et al. Muhicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 1999,17(2) :485.
8Lara F, Dela Garza J, Ramirez T, et al. High pathological response after neoadjuvant chemotherapy with Doxorubicin and docetaxel in locally advanced breast cancer. Proceeding of ASCO, 2000 (19) : 126a.
9Henderson C,Berry DA,Demetri GD,et al.Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node - positive primary breast cancer [J].J Clin Oncol,2003,21 (6):976.
10Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety of humanized anti - HER2monoclonal antibody in women who have HER2 expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease[J].J Clin Oncol,1999,17(9):2 639.
